CEO and President of Optimer Pharmaceuticals Inc. (OPTR, Financial) Michael N Chang buys 18,000 shares of OPTR on 12/29/2009 at an average price of $10.83 a share.
OPTIMER PHARMACEUTICALS, INC. is a biopharmaceutical company focused on discovering, developing & commercializing innovative anti-infective products for the treatment of serious infections. Optimer is currently focused on discovering, developing, & commercializing innovative anti-infective products in diseases of unmet needs and where current therapeutic options have limitations. Optimer has two late-stage anti-infective product candidates. OPT-80, currently in two pivotal Phase 3 clinical trials, is being developed for the treatment of Clostridium difficile infection, the most common hospital-acquired diarrhea. Prulifloxacin, also in two pivotal Phase 3 clinical trials, is an antibiotic being developed for the treatment of travelers' diarrhea, a form of infectious diarrhea. The Company has also licensed technologies and therapeutic targets from The Scripps Research Institute and The Memorial Sloan-Kettering Cancer Center. These licenses form the core of Optimer's carbohydrate Optimer Pharmaceuticals Inc. has a market cap of $360.2 million; its shares were traded at around $10.88 with and P/S ratio of 352.1.
OPTR is in the portfolios of Stanley Druckenmiller of Duquesne Capital Management, LLC.
OPTIMER PHARMACEUTICALS, INC. is a biopharmaceutical company focused on discovering, developing & commercializing innovative anti-infective products for the treatment of serious infections. Optimer is currently focused on discovering, developing, & commercializing innovative anti-infective products in diseases of unmet needs and where current therapeutic options have limitations. Optimer has two late-stage anti-infective product candidates. OPT-80, currently in two pivotal Phase 3 clinical trials, is being developed for the treatment of Clostridium difficile infection, the most common hospital-acquired diarrhea. Prulifloxacin, also in two pivotal Phase 3 clinical trials, is an antibiotic being developed for the treatment of travelers' diarrhea, a form of infectious diarrhea. The Company has also licensed technologies and therapeutic targets from The Scripps Research Institute and The Memorial Sloan-Kettering Cancer Center. These licenses form the core of Optimer's carbohydrate Optimer Pharmaceuticals Inc. has a market cap of $360.2 million; its shares were traded at around $10.88 with and P/S ratio of 352.1.
OPTR is in the portfolios of Stanley Druckenmiller of Duquesne Capital Management, LLC.
CEO Recent Trades:
- Buy:: CEO and President Michael N Chang bought 15,000 shares of OPTR stock on 11/25/2009 at the average price of 11.52, the price of the stock has decreased by 5.56% since.
Directors and Officers Recent Trades:
- Buy:: VP, Clinical Development Youe Kong Shue bought 3,000 shares of OPTR stock on 12/02/2009 at the average price of 10.99, the price of the stock has decreased by 1% since.
- Buy:: COO and SVP Tessie M Che bought 15,000 shares of OPTR stock on 11/25/2009 at the average price of 11.52, the price of the stock has decreased by 5.56% since.
